EG 427

EG 427

Recherche en biotechnologie

Paris, Île-de-France 1 523 abonnés

Pinpoint Gene Therapy

À propos

At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.

Secteur
Recherche en biotechnologie
Taille de l’entreprise
11-50 employés
Siège social
Paris, Île-de-France
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2019
Domaines
Gene therapy, peripheral nervous system disorders, neurogenic bladder, HSV-1 vector platform, urinary bladder dysfunction, Herpes type 1 gene therapy platform et treatment of nervous system disorders

Lieux

Employés chez EG 427

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

EG 427 2 rounds en tout

Dernier round

Série A

5 611 773,00 $US

Voir plus d’informations sur Crunchbase